.jpg?format=webp&width=780)
The use of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of hepatocellular carcinoma (HCC), a type of liver cancer. However, only a fraction of patients respond to the current ICI-based therapies, and there is a need for biomarkers and new treatment strategies for those who do not respond or develop resistance. The recent approval of certain ICI regimens has raised questions about patient selection factors and biomarkers, as well as the best combination and sequencing of therapies. Additionally, there is growing interest in using ICIs in early-stage HCC and in combination with local treatments. The role of ICIs in liver transplantation for HCC patients, either as a bridge to transplant or for post-transplant recurrence, is also an area of investigation due to the risk of rejection. This review provides a summary of key immuno-oncology trials in HCC and discusses potential future developments.
Like
Save
Share